1. Home
  2. INMB vs XBIT Comparison

INMB vs XBIT Comparison

Compare INMB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$1.96

Market Cap

64.7M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.18

Market Cap

66.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INMB
XBIT
Founded
2015
2005
Country
United States
United States
Employees
N/A
87
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.7M
66.8M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
INMB
XBIT
Price
$1.96
$2.18
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $5.40
N/A
AVG Volume (30 Days)
★ 326.7K
43.6K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 11.85
N/A
EPS
★ N/A
N/A
Revenue
★ $50,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 257.14
N/A
52 Week Low
$1.09
$2.09
52 Week High
$2.60
$3.44

Technical Indicators

Market Signals
Indicator
INMB
XBIT
Relative Strength Index (RSI) 40.57 43.06
Support Level $1.21 $2.17
Resistance Level $2.17 $2.48
Average True Range (ATR) 0.17 0.04
MACD -0.05 0.00
Stochastic Oscillator 0.00 30.77

Price Performance

Historical Comparison
INMB
XBIT

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: